Avanços no tratamento da Síndrome da Bronquiolite Obliterante pós-transplante de células-tronco hematopoiéticas - uma revisão de escopo
Advances in the treatment of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a scoping review
Gabriela Spessatto; Isabela Grazia de Campos; Guilherme da Silva Martins; Bruno Hernandes David João; Juliana Gonçalves Primon; Thalita Gonçalves Picciani; Herberto José Chong-Neto1; Nelson Augusto Rosário-Filho; Débora Carla Chong-Silva
Resumo
O Transplante de Células-Tronco Hematopoiéticas (TCTH) é o tratamento de escolha para uma variedade de doenças neoplá-sicas e não neoplásicas em crianças. No entanto, complicações respiratórias no pós-transplante são comuns e resultam em aumento dos índices de morbidade e mortalidade. A Doença Enxerto Contra Hospedeiro (DECH) está entre as principais complicações na fase tardia, sendo a síndrome da bronquiolite obliterante (BOs), a síndrome clínica mais frequente. Caracteriza-se pelo padrão obstrutivo e de caráter progressivo, ocasionado pela obliteração da pequena via aérea. É uma condição desafiadora, uma vez que não existe tratamento específico com eficácia comprovada, além da escassez de dados na população pediátrica. O objetivo deste artigo é revisar estudos que apontam a efetividade dos tratamentos existentes para esta condição, nas diferentes modalidades, desde as terapias convencionais até as abordagens mais atuais, buscando informar os médicos assistentes envolvidos no atendimento deste grupo de pacientes. O manejo preciso e eficaz da BOs é fundamental para interromper o comprometimento da função pulmonar em médio e longo prazo, favorecendo uma maior sobrevida para os pacientes no pós-TCTH.
Palavras-chave
Referências
1. Yoshihara S,Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and otherlate-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Jul;13(7):749-59.
2. Chong-Silva DC, Schneider PM, Jardim TAP, Nichele S, Loth G, Riedi CA, et al. Pulmonary complications after hematopoietic stem cell transplantation in children: a functional and tomographic evaluation. J Bras Pneumol. 2022 Sep 26;48(5):e20220134.
3. Afessa B, Abdulai RM, Kremers WK, Hogan WJ, Litzow MR, Peters SG. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest. 2012 Feb;141(2):442-50.
4. Elssner A, Jaumann F, Dobmann S, Behr J, Schwaiblmair M, Reichenspurner H, et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation. 2000 Jul 27;70(2):362-7.
5. Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017 Jan;129(4):448-55.
6. Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, et al.; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation Workshop Participants. Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Ann Am Thorac Soc. 2021 Mar;18(3):381-94.
7. Bergeron A, Cheng GS. Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017 Dec;38(4):607-21.
8. Kavaliunaite E, Aurora P. Diagnosing and managing bronchio-litis obliterans in children. Expert Rev Respir Med. 2019;13(5):481-8.
9. Glanville AR, Benden C, Bergeron A, Cheng GS, Gottlieb J, Lease ED, et al. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Res. 2022 Jul 25;8(3):00185-2022.
10. Cavallaro D, Guerrieri M, Cattelan S, Fabbri G, Croce S, Armati M, et al., Tuscany Transplant Group, Bergantini L. Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective. Biomedicines. 2022 Dec 17;10(12):3277.
11. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, eds. JBI Manual for Evidence Synthesis. JBI; 2024. Disponível em: https://synthesismanual.jbi.global. doi: 10.46658/JBIMES-24-01.
12. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT : a case series of eight patients. Bone Marrow Transplant. 2011 Oct;46(10):1369-73.
13. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant. 2005 Jul;36(2):135-8.
14. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: arandomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002 Jul 1;100(1):48-51.
15. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020 Feb;7(2):e157-e167.
16. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006 Sep 1;174(5):566-70.
17. Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study. Bone Marrow Transplant. 2011 Dec;46(12):1551-6.
18. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005 Mar;25(3):490-3.
19. Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al.; ALLOZITHRO Study Investigators. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA. 2017 Aug 8;318(6):557-66.
20. Cheng GS, Bondeelle L, Gooley T, He Q, Jamani K, Krakow EF, et al. Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Feb;26(2):392-400.
21. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT : a case series of eight patients. Bone Marrow Transplant. 2011 Oct;46(10):1369-73.
22. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr;22(4):710-6.
23. Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015 Jun 1;191(11):1242-9.
24. Kim SW, Rhee CK, Kim YJ, Lee S, Kim HJ, Lee JW. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Respir Res. 2016 May 26;17(1):63.
25. Lim JU, Park S, Yoon JH, Lee SE, Cho BS, Kim YJ, et al. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. Respir Med. 2023 Nov;218:107410.
26. Rhee CK, Yoshisue H, Lad R. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Adv Ther. 2019 Mar;36(3):495-519.
27. Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011 Mar;46(3):426-9.
28. Asensi Cantó P, Sanz Caballer J, Solves Alcaína P, de la Rubia Comos J, Gómez Seguí I. Extracorporeal Photopheresis in Graft-versus-Host Disease. Transplant Cell Ther. 2023 Sep;29(9):556-66.
29. Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, et al. Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Jul;18(7):1044-54.
30. Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics. 2005 Sep;116(3):767-70. doi: 10.1542/peds.2005-0806. PMID: 16140721.
31. Brownback KR, Thomas LA, McGuirk JP, Ganguly S, Streiler C, Abhyankar S. Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. Lung. 2017 Dec;195(6):781-8. doi: 10.1007/s00408-017-0051-0. Epub 2017 Sep 11. PMID: 28894914.
32. Chen S, Zhao K, Lin R, Wang S, Fan Z, Huang F, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study. EBioMedicine. 2019 Nov;49:213-22.
33. Athale J, Gormley NJ, Reger R, Alsaaty A, Reda D, Worthy T, et al. Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bronchiolitis Obliterans Syndrome (BOS). Blood. 2019;134 (Supplement 1):4552.
34. Faraci M, Ricci E, Bagnasco F, Pierri F, Giardino S, Girosi D, et al. Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. Pediatr Pulmonol. 2020 Mar;55(3):631-7.
35. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. doi: 10.1016/j.cytogfr.2013.04.003.
36. Jeon Y, Lim JY, Im KI, Kim N, Cho SG. BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis. Front Immunol. 2022 Dec 6;13:995149. doi: 10.3389/fimmu.2022.995149.
37. Pusic I, Johanns T, Sarantopoulos S, Westervelt P, Cashen A, Uy G, et al. Use of belimumab for prophylaxis of chronic graft-versus-host disease. Presented at: 2022 Tandem Meetings Transplantation & Cellular Therapy Meetings of ACTCT and CIBMTR; April 23-26, 2022; Salt Lake City, UT. Abstract 34.
38. Tang W,Yu T, Dong T, LiuT, Ji J. Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation. Chest. 2020 Sep;158(3):e89-e91.
39. Matthaiou EI, Sharifi H, O'Donnell C, Chiu W, Owyang C, Chatterjee P, et al. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplant. 2022 Aug;57(8):1319-1326. doi: 10.1038/s41409-022-01716-4.
40. Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann Thorac Surg. 2005 Mar;79(3):1051-2.
41. Rabitsch W, Deviatko E, Keil F, Herold C, Dekan G, Greinix HT, et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation. 2001 May 15;71(9):1341-3.
42. A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Submetido em:
31/10/2024
Aceito em:
21/12/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email